ERYTHROCYTE SEDIMENTATION-RATE AS A TUMOR-MARKER IN HUMAN PROSTATIC-CANCER - AN ANALYSIS OF PROGNOSTIC FACTORS IN 300 POPULATION-BASED CONSECUTIVE CASES

被引:0
作者
JOHANSSON, JE
SIGURDSSON, T
HOLMBERG, L
BERGSTROM, R
机构
[1] UNIV UPPSALA,CANC EPIDEMIOL UNIT,S-75105 UPPSALA,SWEDEN
[2] UNIV UPPSALA,DEPT SURG,S-75105 UPPSALA,SWEDEN
[3] UNIV UPPSALA,DEPT STAT,S-75105 UPPSALA,SWEDEN
关键词
PROSTATIC CANCER; ERYTHROCYTE SEDIMENTATION RATE; PROGNOSTIC FACTOR; TUMOR MARKER;
D O I
10.1002/1097-0142(19920915)70:6<1556::AID-CNCR2820700619>3.0.CO;2-I
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. The natural history of prostatic cancer is variable. Our knowledge of prognostic factors is limited; therefore, research is needed. Methods. The cases of 300 population-based consecutive patients with a diagnosis of cancer of the prostate were analyzed regarding different prognostic factors (but with special reference to the erythrocyte sedimentation rate [ESR]). Results. After a mean observation time of 100 months, M category, ESR, grade, performance status, hemoglobin level, and T category were found to correlate with disease-specific death using multivariate analysis. The variables correlating with progression in the multivariate model were M category, ESR, T category, grade, treatment, and age. Patients treated with estrogen had a significantly lower risk (relative hazard, 0.3) of relapse. ESR was highly statistically significant (P < 0.0001) as a prognostic factor. With the variable in linear form, a 20-mm/h higher level suggested a 29% increased risk, on average, for dying of prostatic cancer (using a best-fit multivariate model). However, the relationship was not linear. After correcting for the effect of other factors, the risk for dying of prostatic cancer was lowest when the ESR was 40-50 mm/h and highest when its values were highest. Conclusions. ESR is an indicator of increased risk of progression and death in prostatic cancer. Other prognostic factors such as M and T categories, grade, performance status, hemoglobin level, and age currently are more important when planning treatment. It is possible that the ESR reflects aspects of tumor-host relationship and that both a low and high ESR are markers for patients with receding host defence mechanism.
引用
收藏
页码:1556 / 1563
页数:8
相关论文
共 40 条
[1]  
ADAMI HO, 1980, SCAND J UROL NEPHROL, V20, P107
[2]  
Adolfsson R, 1977, Scand J Soc Med Suppl, V14, P122
[3]  
Byar D, 1984, CONTROLLED CLIN TRIA, P147
[4]  
CORRIERE JN, 1970, CANCER, V25, P911, DOI 10.1002/1097-0142(197004)25:4<911::AID-CNCR2820250426>3.0.CO
[5]  
2-Y
[6]  
COX DR, 1972, J R STAT SOC B, V34, P187
[7]   MULTIVARIATE-ANALYSIS OF PROGNOSTIC FACTORS IN PATIENTS WITH ADVANCED PROSTATIC-CANCER - RESULTS FROM 2 EUROPEAN ORGANIZATION FOR RESEARCH ON TREATMENT OF CANCER TRIALS [J].
DEVOOGT, HJ ;
SUCIU, S ;
SYLVESTER, R ;
PAVONEMACALUSO, M ;
SMITH, PH ;
DEPAUW, M .
JOURNAL OF UROLOGY, 1989, 141 (04) :883-888
[8]  
DINARELLO CA, 1984, NEW ENGL J MED, V311, P1413
[9]  
ECANOW B, 1976, SCIENCE, V193, P919
[10]   ENDOCRINE THERAPY IN CARCINOMA OF THE PROSTATE GLAND - 10-YEAR SURVIVAL STUDIES [J].
EMMETT, JL ;
GREENE, LF ;
PAPANTONIOU, A .
JOURNAL OF UROLOGY, 1960, 83 (04) :471-484